Dermatology Times December 2024 Recap

Author(s):

Emma Andrus, Associate Editor

Key Takeaways

Yesintek, a Stelara biosimilar, gains FDA approval for psoriasis and psoriatic arthritis, with a 2025 launch anticipated.
Delgocitinib significantly reduces inflammation in chronic hand eczema, acting as a topical pan-JAK inhibitor.
An AI model achieves 81% accuracy in diagnosing onychomycosis, offering fast and reliable assessments.
SB5, an adalimumab biosimilar, demonstrates long-term efficacy and safety in psoriasis treatment with 2.5 years average persistence.
Johnson & Johnson submits sBLAs for guselkumab to treat pediatric psoriasis and juvenile psoriatic arthritis.

Dermatology Times is looking back on the top stories in dermatology from the month of December.

Clearances, Approvals, Updates, and Recommendations

ICYMI: FDA Greenlights Yesintek, Sixth Biosimilar to Stelara, for Psoriasis and Psoriatic Arthritis

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

Big Studies and Big Data

Delgocitinib Reduces Inflammation and Restores Skin Barrier in CHE as a Topical Pan-JAK Inhibitor

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Novel AI Model Can Accurately Diagnose Onychomycosis

The algorithm demonstrated 81% accuracy, promising fast, reliable, and reproducible assessments for patients.

UV and Outdoor Sports: The Importance of Coaches in Educating Athletes

Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.

SB5 is Effective and Safe for Long-Term Psoriasis Treatment

The adalimumab biosimilar had an average persistence of 2.5 years, according to this British study.

Market and Pharma News, Drug Watch

Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Apogee Announces Clinical Trial Advancements in APG777 for AD Treatment

Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.

Dermatology Times Hosts Inaugural Horizons in Advanced Practice Meeting

The exclusive event brought together physician assistants and nurse practitioners from across the country to review atopic dermatitis and psoriasis patient cases.

Strides for Skin Health Equity

Navigating Challenges and Inspiring Advocacy: A Pre-Med Student's Journey With HS

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Several Risk Factors, Including PAE, Associated with Acne Scarring in Thai Patients

Researchers noted higher correlations in those who are prone to severe acne and post acne erythema (PAE).

Psoriasis Patients Without Insurance Are More Likely Unable to Obtain Care

The effect of insurance status on US patients with psoriasis can help identify those at risk of being undertreated.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.